| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
1 Laboratory of Antineoplastic Pharmacology and 2 Gynecologic Oncology Unit, Università Cattolica Sacro Cuore, Rome, Italy and Departments of 3 Pathology and Histology and 4 Oncology, Università Cattolica Sacro Cuore, Campobasso, Italy
Requests for reprints: Giovanni Scambia, Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynaecology Università Cattolica Sacro Cuore, L.go Agostino Gemelli 8 00168 Rome, Italy. Phone: 635-502-407; Fax: 635-508-736; E-mail: cferlini{at}rm.unicatt.it.
The vast majority of women with advanced ovarian cancer will ultimately relapse and develop a drug-resistant disease with an overall 5-year survival of <50%. Unfortunately, the mechanisms of drug resistance actually operating in patients are still unknown. To address this issue, in 41 patients affected by advanced ovarian cancer the three main mechanisms of paclitaxel resistance were investigated: overexpression of MDR-1 gene, point mutations at prominently expressed 
-tubulin and ß-tubulin genes and selective alterations in the expression of ß-tubulin isotypes. MDR-1 and the ß-tubulin isotypes expression were evaluated by semiquantitative and real-time PCR. On the same specimens, quantitative immunohistochemistry was also done in the tumor area. No statistically significant changes of MDR-1 expression were noticed between the sensitive and resistant patients either at the mRNA or protein level. The tubulin mutations for the ubiquitous -tubulin and ß-tubulin genes were evaluated by automated DNA sequencing, and in all patients, no mutations were detected in both resistant and sensitive cases. With regard to the expression of tubulin isoforms, a statistically significant up-regulation of class III ß-tubulin was found in the resistant subset. It is worth noting that this statistically significant increase of the expression of class III ß-tubulin was detectable at the mRNA and protein level. By a direct comparison of the three main known mechanisms of paclitaxel resistance, this study indicates that overexpression of class III ß-tubulin is the most prominent mechanism of paclitaxel resistance in ovarian cancer.
Key Words: Drug Resistance • Paclitaxel • Ovarian Cancer
This article has been cited by other articles:
|
|
 |
|
  O. Kutuk and A. Letai Alteration of the Mitochondrial Apoptotic Pathway Is Key to Acquired Paclitaxel Resistance and Can Be Reversed by ABT-737 Cancer Res., October 1, 2008; 68(19): 7985 - 7994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Galmarini, I. Treilleux, F. Cardoso, C. Bernard-Marty, V. Durbecq, D. Gancberg, M.-C. Bissery, M. Paesmans, D. Larsimont, M. J. Piccart, et al. Class III {beta}-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel Clin. Cancer Res., July 15, 2008; 14(14): 4511 - 4516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cicchillitti, R. Penci, M. Di Michele, F. Filippetti, D. Rotilio, M. B. Donati, G. Scambia, and C. Ferlini Proteomic characterization of cytoskeletal and mitochondrial class III {beta}-tubulin Mol. Cancer Ther., July 1, 2008; 7(7): 2070 - 2079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ishibashi, K. Nakayama, S. Yeasmin, A. Katagiri, K. Iida, N. Nakayama, M. Fukumoto, and K. Miyazaki A BTB/POZ Gene, NAC-1, a Tumor Recurrence-Associated Gene, as a Potential Target for Taxol Resistance in Ovarian Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3149 - 3155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Luchko, J. T. Huzil, M. Stepanova, and J. Tuszynski Conformational Analysis of the Carboxy-Terminal Tails of Human {beta}-Tubulin Isotypes Biophys. J., March 15, 2008; 94(6): 1971 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Hwang, A. Rait, K. F. Pirollo, Q. Zhou, V. M. Yenugonda, G. M. Chinigo, M. L. Brown, and E. H. Chang Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue Mol. Cancer Ther., March 1, 2008; 7(3): 559 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Vahdat Ixabepilone: A Novel Antineoplastic Agent with Low Susceptibility to Multiple Tumor Resistance Mechanisms Oncologist, March 1, 2008; 13(3): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Prislei, S. Mozzetti, F. Filippetti, M. De Donato, G. Raspaglio, L. Cicchillitti, G. Scambia, and C. Ferlini From plasma membrane to cytoskeleton: a novel function for semaphorin 6A Mol. Cancer Ther., January 1, 2008; 7(1): 233 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Gan, E. Pasquier, and M. Kavallaris Class III {beta}-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non Small Cell Lung Cancer Cancer Res., October 1, 2007; 67(19): 9356 - 9363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Seve, R. Lai, K. Ding, T. Winton, C. Butts, J. Mackey, C. Dumontet, L. Dabbagh, S. Aviel-Ronen, L. Seymour, et al. Class III {beta}-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10 Clin. Cancer Res., February 1, 2007; 13(3): 994 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Esteve, M. Carre, V. Bourgarel-Rey, A. Kruczynski, G. Raspaglio, C. Ferlini, and D. Braguer Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol. Cancer Ther., November 1, 2006; 5(11): 2824 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van Amerongen and A. Berns TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes & Dev., August 1, 2006; 20(15): 1975 - 1981. [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrandina, G. F. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, S. Mozzetti, G. Scambia, and C. Ferlini Class III {beta}-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients. Clin. Cancer Res., May 1, 2006; 12(9): 2774 - 2779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Seve, J. Mackey, S. Isaac, O. Tredan, P.-J. Souquet, M. Perol, R. Lai, A. Voloch, and C. Dumontet Class III {beta}-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel Mol. Cancer Ther., December 1, 2005; 4(12): 2001 - 2007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Seve, S. Isaac, O. Tredan, P.-J. Souquet, Y. Pacheco, M. Perol, L. Lafanechere, A. Penet, E.-L. Peiller, and C. Dumontet Expression of Class III {beta}-Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy Clin. Cancer Res., August 1, 2005; 11(15): 5481 - 5486. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
